Chinese coronavirus vaccine could be tested, manufactured
in Canada
Reuters Reuters Tue, May 12 11:33 PM GMT+8
Reactions Reblog on Tumblr Share Tweet Email
TORONTO (Reuters) - China's CanSino Biologics Inc, the
company behind one of the few coronavirus vaccine candidates already in
clinical trials, is collaborating with Canada's National Research Council to
"pave the way" for future trials in Canada, the research council said
on Tuesday.
The NRC said it would scale up a
production process for CanSino's vaccine at a government facility in Montreal,
and that CanSino was preparing a trial application for drug regulator Health
Canada.
If CanSino's vaccine
works, the collaboration could help ensure that Canadians have access to it.
Local trial data could reassure Health Canada that the vaccine is safe, and
local manufacturing could ensure some doses are at hand.
Asked whether the collaboration would make it possible for
Health Canada to consider data gathered in China, NRC said that in general,
data can be shared with the regulator's approval.
"Canadian clinical trials will expand on Chinese data
and provide an enhanced understanding of the vaccine candidate's safety
profile," the agency said.
A vaccine that protects people from the coronavirus could
end the pandemic, but finding one that works and manufacturing enough doses is
a huge challenge.
Relations between Canada and China have been strained since
Canadian authorities arrested Huawei Chief Financial Officer Meng Wanzhou on Dec.
1, 2018 at the request of the United States. Her arrest infuriated the Chinese
government, which subsequently detained two Canadian citizens - Michael Kovrig
and Michael Spavor - on state security charges.
But in the midst of the pandemic, Canada has struggled to
import protective equipment from the United States, turning in part to
suppliers in China. A federal procurement website notes that Canada has
"established on-the-ground support in China" to manage bulk
purchases.
CanSino and the NRC have worked together since 2013, and the
company's vaccine is produced using a cell line that was developed at the NRC,
the agency said.
CanSino Chairman Xuefeng Yu worked in Canada from 1996 to
2009, according to the company's website, mainly for Sanofi.
Shares of Hong Kong-listed CanSino rose on April 26 after
the company said Health Canada had agreed to meet to discuss a clinical trial
application. [FWN2CD00V]
Separately on Tuesday, Canada
promised C$600 million to replenish the GAVI vaccine alliance, to support
routine vaccinations around the world. GAVI is also helping low-income
countries respond to coronavirus outbreaks.
(Reporting by Allison Martell; Editing by Dan Grebler)
Translation
多倫多(路透社) - 研究委員會週二表示,中國CanSino生物製劑公司(CanSinoBiologicsInc.)正在與NRC (加拿大國家研究委員會)
合作,為未來在加拿大的試驗"鋪平道路"。
NRC表示,
將在蒙特利爾的一家政府設施擴大CanSino疫苗的生產流程,
而CanSino正在準備向加拿大衛生部藥物監管機構作試驗申請。
如果CanSino的疫苗有效,這種合作可以幫助確保加拿大人能夠獲得疫苗。當地試驗數據可以讓加拿大衛生部放心疫苗是安全的, 而在當地製造可以確保一些劑量可以在手中。
當被問及此次合作是否使加拿大衛生部能夠考慮在中國收集的數據時,NRC表示,一般來說,
共用數據可以經監管機構批准。
該機構表示:「加拿大的臨床試驗將擴大中國數據,
並提供對疫苗候選者安全狀況的深層瞭解。
保護人們免受冠狀病毒侵害的疫苗可以結束這一大流行,但找到一種有功效並能製造出足夠劑量的疫苗是一個巨大的挑戰。
自2018年12月1日加拿大當局應美國要求逮捕華為首席財務官孟萬洲以來,加拿大和中國的關係一直處於緊張狀態。她的被捕激怒了中國政府,
中國政府隨後以國家安全罪名拘留了兩名加拿大公民——邁克爾·科弗裡格和邁克爾·斯帕沃爾。
但在大流行期間,加拿大一直努力從美國進口防護設備,
部分轉向中國的供應商。一家聯邦採購網站指出,
加拿大"在中國建立了實地支援",
以便管理大宗採購。
根據公司網站, CanSino董事長余雪峰於1996年至2009年在加拿大主要為賽諾菲公司工作。
在該公司在表示加拿大衛生部已同意召開會議討論臨床試驗申請之后,在4月26日在香港上市的CanSino股價上漲。[FWN2CD00V]
另外,加拿大在周二承諾提供6億加元去補充全球疫苗和免疫聯盟(GAVI
vaccine alliance), 用以支援世界各地的常規疫苗接種。該聯盟還幫助低收入國家應對冠狀病毒爆發。
Based on
the argument of the French, this vaccine should belong to all the people
in the world and it is not something between Canada and China alone.
沒有留言:
張貼留言